标题
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
作者
关键词
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Overall Response Rate, Chronic Lymphocytic Leukemia Patient, Chronic Lymphocytic Leukemia Cell
出版物
Journal of Hematology & Oncology
Volume 9, Issue 1, Pages -
出版商
Springer Nature
发表日期
2016-03-09
DOI
10.1186/s13045-016-0250-9
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia
- (2015) J. R. Brown et al. BLOOD
- A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies
- (2015) H. S. Walter et al. BLOOD
- The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity inCXCR4Wild-typeandCXCR4WHIMmutated Waldenstrom macroglobulinaemia cells
- (2015) Yang Cao et al. BRITISH JOURNAL OF HAEMATOLOGY
- Abstract 2597: BGB-3111 is a novel and highly selective Bruton's tyrosine kinase (BTK) inhibitor
- (2015) Na Li et al. CANCER RESEARCH
- Abstract 2596: ACP-196: a novel covalent Bruton's tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients
- (2015) Todd Covey et al. CANCER RESEARCH
- Abstract 408: ACP-196, an orally bioavailable covalent selective inhibitor of Btk, modulates the innate tumor microenvironment, exhibits antitumor efficacy and enhances gemcitabine activity in pancreatic cancer
- (2015) Brian J. Lannutti et al. CANCER RESEARCH
- Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma
- (2015) Q. Yang et al. CLINICAL CANCER RESEARCH
- Novel ALK inhibitors in clinical use and development
- (2015) Chaitanya Iragavarapu et al. Journal of Hematology & Oncology
- Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia
- (2015) Kanti R. Rai Journal of Hematology & Oncology
- Galectin-3 mediates bone marrow microenvironment-induced drug resistance in acute leukemia cells via Wnt/β-catenin signaling pathway
- (2015) Kaimin Hu et al. Journal of Hematology & Oncology
- AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
- (2015) Jingjing Wu et al. Journal of Hematology & Oncology
- ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
- (2015) Shundong Cang et al. Journal of Hematology & Oncology
- Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
- (2015) Jingjing Wu et al. Journal of Hematology & Oncology
- Blinatumomab: a new era of treatment for adult ALL?
- (2015) Xavier Thomas LANCET ONCOLOGY
- A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+tumor cells
- (2015) Uwe Reusch et al. mAbs
- MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia
- (2015) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
- (2015) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abstract 1744: ACP-196: A second generation Btk inhibitor demonstrates biologic activity in a canine model of B-cell non-Hodgkin lymphoma
- (2015) Heather L. Gardner* et al. CANCER RESEARCH
- Abstract 1757: The novel BTK inhibitor CC-292 exerts in vitro and in vivo antitumor activity, interferes with adhesion, cell migration, and synergizes with lenalidomide in MCL models
- (2015) Anna Vidal-Crespo et al. CANCER RESEARCH
- Abstract 2624: The novel Bruton's tyrosine kinase inhibitor ACP-196 showsin vivoefficacy against human chronic lymphocytic leukemia cells xenografted to the NSG mouse model
- (2015) Carsten U. Niemann et al. CANCER RESEARCH
- New antibody approaches to lymphoma therapy
- (2014) Tejas Suresh et al. Journal of Hematology & Oncology
- Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents
- (2014) Kaushal Parikh et al. Journal of Hematology & Oncology
- Movement toward Optimization of CLL Therapy
- (2014) Kanti R. Rai et al. NEW ENGLAND JOURNAL OF MEDICINE
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modeling tumor–host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy
- (2013) S E M Herman et al. LEUKEMIA
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started